Atomoxetine and Stimulant Medications in Children and Adolescents with Persistent Symptoms of Attention Deficit Hyperactivity Disorder despite Monotherapy

American Academy of Pediatrics. ADHD: clinical practice guideline for the diagnosis, evaluation and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011:128:1–16.

CADDRA Canadian ADHD practice guidelines. 3rd ed. Toronto (ON): Canadian Attention Deficit Hyperactivity Disorder Resource Alliance; 2011. Available: www.caddra.ca (accessed May 6, 2012).

Dopheide JA . ASHP therapeutic position statement on the appropriate use of medications in the treatment of attention-deficit/hyperactivity disorder in pediatric patients. Am J Health Syst Pharm 2005;62:1502–9.

Hanwella R Senanayake M de Silva V . Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry 2011;11:176–83.

Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. NICE clinical guideline 72. London (UK): National Institute for Health and Clinical Excellence; 2008. Available: www.nice.org.uk/CG072 (accessed May 6, 2012).

Brown TE . Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports. J Child Adolesc Psychopharmacol 2004;14:129–36.

Jaworowski S Benarroch F Gross-Tsur V . Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome. J Child Adolesc Psychopharmacol 2006;16:365–70.

Niederhofer H . Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD? Psychiatr Danub 2009;21:330.

Carlson GA Dunn D Kelsey D . A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health 2007;1:10.

Wilens TE Hammerness P Utzinger L An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. J Child Adolesc Psychopharmacol 2009;19:485–92.

Hammerness P Georgiopoulos A Doyle RL An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J Child Adolesc Psychopharmacol 2009;19:493–9.

Supplemental information: Implementing the key action statements: an algorithm and explanation for process of care for the evaluation, diagnosis, treatment and monitoring of ADHD in children and adolescents. Elk Grove Village (IL): American Academy of Pediatrics; 2011. Available: http://pediatrics.aappublications.org/content/suppl/2011/10/11/peds.2011-2654.DCl/zpe611117822p.pdf (accessed May 17, 2012).

Pliszka SR Crismon ML Hughes CW ; Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:642–57.